2-cyclohexyl-N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]acetamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]acetamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-2-methylbutanamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-2-naphthalen-2-ylacetamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-4-phenylbutanamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-3-phenylpropanamide

C148H138N18O12 — CID 157293632

IUPAC2-cyclohexyl-N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]acetamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]acetamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-2-methylbutanamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-2-naphthalen-2-ylacetamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-4-phenylbutanamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-3-phenylpropanamide
SMILESCC(=O)Nc1ncc(-c2ccccc2)nc1C(O)c1ccccc1.CCC(C)C(=O)Nc1ncc(-c2ccccc2)nc1C(O)c1ccccc1.O=C(CC1CCCCC1)Nc1ncc(-c2ccccc2)nc1C(O)c1ccccc1.O=C(CCCc1ccccc1)Nc1ncc(-c2ccccc2)nc1C(O)c1ccccc1.O=C(CCc1ccccc1)Nc1ncc(-c2ccccc2)nc1C(O)c1ccccc1.O=C(Cc1ccc2ccccc2c1)Nc1ncc(-c2ccccc2)nc1C(O)c1ccccc1
InChIInChI=1S/C29H23N3O2.C27H25N3O2.C26H23N3O2.C25H27N3O2.C22H23N3O2.C19H17N3O2/c33-26(18-20-15-16-21-9-7-8-14-24(21)17-20)32-29-27(28(34)23-12-5-2-6-13-23)31-25(19-30-29)22-10-3-1-4-11-22;31-24(18-10-13-20-11-4-1-5-12-20)30-27-25(26(32)22-16-8-3-9-17-22)29-23(19-28-27)21-14-6-2-7-15-21;30-23(17-16-19-10-4-1-5-11-19)29-26-24(25(31)21-14-8-3-9-15-21)28-22(18-27-26)20-12-6-2-7-13-20;29-22(16-18-10-4-1-5-11-18)28-25-23(24(30)20-14-8-3-9-15-20)27-21(17-26-25)19-12-6-2-7-13-19;1-3-15(2)22(27)25-21-19(20(26)17-12-8-5-9-13-17)24-18(14-23-21)16-10-6-4-7-11-16;1-13(23)21-19-17(18(24)15-10-6-3-7-11-15)22-16(12-20-19)14-8-4-2-5-9-14/h1-17,19,28,34H,18H2,(H,30,32,33);1-9,11-12,14-17,19,26,32H,10,13,18H2,(H,28,30,31);1-15,18,25,31H,16-17H2,(H,27,29,30);2-3,6-9,12-15,17-18,24,30H,1,4-5,10-11,16H2,(H,26,28,29);4-15,20,26H,3H2,1-2H3,(H,23,25,27);2-12,18,24H,1H3,(H,20,21,23)
InChIKeyBBBXDUFHWFPVRX-UHFFFAOYSA-N
MW2360.85 g/mol
LogP28.07
Rot. Bonds37

About 2-cyclohexyl-N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]acetamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]acetamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-2-methylbutanamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-2-naphthalen-2-ylacetamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-4-phenylbutanamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-3-phenylpropanamide

2-cyclohexyl-N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]acetamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]acetamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-2-methylbutanamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-2-naphthalen-2-ylacetamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-4-phenylbutanamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-3-phenylpropanamide (PubChem CID 157293632) has the molecular formula C148H138N18O12 and a molecular weight of 2360.85 g/mol. Its IUPAC name is 2-cyclohexyl-N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]acetamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]acetamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-2-methylbutanamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-2-naphthalen-2-ylacetamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-4-phenylbutanamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-3-phenylpropanamide.

Molecular Properties

Compound Name2-cyclohexyl-N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]acetamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]acetamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-2-methylbutanamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-2-naphthalen-2-ylacetamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-4-phenylbutanamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-3-phenylpropanamide
PubChem CID157293632
Molecular FormulaC148H138N18O12
Molecular Weight2360.85 g/mol
Exact Mass2359.07
IUPAC Name2-cyclohexyl-N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]acetamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]acetamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-2-methylbutanamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-2-naphthalen-2-ylacetamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-4-phenylbutanamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-3-phenylpropanamide
SMILESCC(=O)Nc1ncc(-c2ccccc2)nc1C(O)c1ccccc1.CCC(C)C(=O)Nc1ncc(-c2ccccc2)nc1C(O)c1ccccc1.O=C(CC1CCCCC1)Nc1ncc(-c2ccccc2)nc1C(O)c1ccccc1.O=C(CCCc1ccccc1)Nc1ncc(-c2ccccc2)nc1C(O)c1ccccc1.O=C(CCc1ccccc1)Nc1ncc(-c2ccccc2)nc1C(O)c1ccccc1.O=C(Cc1ccc2ccccc2c1)Nc1ncc(-c2ccccc2)nc1C(O)c1ccccc1
InChIInChI=1S/C29H23N3O2.C27H25N3O2.C26H23N3O2.C25H27N3O2.C22H23N3O2.C19H17N3O2/c33-26(18-20-15-16-21-9-7-8-14-24(21)17-20)32-29-27(28(34)23-12-5-2-6-13-23)31-25(19-30-29)22-10-3-1-4-11-22;31-24(18-10-13-20-11-4-1-5-12-20)30-27-25(26(32)22-16-8-3-9-17-22)29-23(19-28-27)21-14-6-2-7-15-21;30-23(17-16-19-10-4-1-5-11-19)29-26-24(25(31)21-14-8-3-9-15-21)28-22(18-27-26)20-12-6-2-7-13-20;29-22(16-18-10-4-1-5-11-18)28-25-23(24(30)20-14-8-3-9-15-20)27-21(17-26-25)19-12-6-2-7-13-19;1-3-15(2)22(27)25-21-19(20(26)17-12-8-5-9-13-17)24-18(14-23-21)16-10-6-4-7-11-16;1-13(23)21-19-17(18(24)15-10-6-3-7-11-15)22-16(12-20-19)14-8-4-2-5-9-14/h1-17,19,28,34H,18H2,(H,30,32,33);1-9,11-12,14-17,19,26,32H,10,13,18H2,(H,28,30,31);1-15,18,25,31H,16-17H2,(H,27,29,30);2-3,6-9,12-15,17-18,24,30H,1,4-5,10-11,16H2,(H,26,28,29);4-15,20,26H,3H2,1-2H3,(H,23,25,27);2-12,18,24H,1H3,(H,20,21,23)
InChIKeyBBBXDUFHWFPVRX-UHFFFAOYSA-N
XLogP28.07
TPSA450.66 Ų
H-Bond Donors12
H-Bond Acceptors24
Rotatable Bonds37
Heavy Atoms178
Complexity—

Lipinski Rule of Five

4 violations

RuleValue
MW ≤ 5002360.85
LogP ≤ 528.07
H-Bond Donors ≤ 512
H-Bond Acceptors ≤ 1024

Analyze 2-cyclohexyl-N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]acetamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]acetamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-2-methylbutanamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-2-naphthalen-2-ylacetamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-4-phenylbutanamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-3-phenylpropanamide with MolForge

Explore ADMET properties, 3D molecular structure, drug-likeness score, and discover similar compounds using our AI-powered platform.

Launch Full Analysis

Frequently Asked Questions

What is the IUPAC name of 2-cyclohexyl-N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]acetamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]acetamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-2-methylbutanamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-2-naphthalen-2-ylacetamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-4-phenylbutanamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-3-phenylpropanamide?
The IUPAC name of 2-cyclohexyl-N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]acetamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]acetamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-2-methylbutanamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-2-naphthalen-2-ylacetamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-4-phenylbutanamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-3-phenylpropanamide (CID 157293632) is 2-cyclohexyl-N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]acetamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]acetamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-2-methylbutanamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-2-naphthalen-2-ylacetamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-4-phenylbutanamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-3-phenylpropanamide.
What is the SMILES notation for 2-cyclohexyl-N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]acetamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]acetamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-2-methylbutanamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-2-naphthalen-2-ylacetamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-4-phenylbutanamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-3-phenylpropanamide?
The canonical SMILES for 2-cyclohexyl-N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]acetamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]acetamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-2-methylbutanamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-2-naphthalen-2-ylacetamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-4-phenylbutanamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-3-phenylpropanamide is CC(=O)Nc1ncc(-c2ccccc2)nc1C(O)c1ccccc1.CCC(C)C(=O)Nc1ncc(-c2ccccc2)nc1C(O)c1ccccc1.O=C(CC1CCCCC1)Nc1ncc(-c2ccccc2)nc1C(O)c1ccccc1.O=C(CCCc1ccccc1)Nc1ncc(-c2ccccc2)nc1C(O)c1ccccc1.O=C(CCc1ccccc1)Nc1ncc(-c2ccccc2)nc1C(O)c1ccccc1.O=C(Cc1ccc2ccccc2c1)Nc1ncc(-c2ccccc2)nc1C(O)c1ccccc1.
What is the InChIKey of 2-cyclohexyl-N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]acetamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]acetamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-2-methylbutanamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-2-naphthalen-2-ylacetamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-4-phenylbutanamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-3-phenylpropanamide?
The InChIKey is BBBXDUFHWFPVRX-UHFFFAOYSA-N. The full InChI is InChI=1S/C29H23N3O2.C27H25N3O2.C26H23N3O2.C25H27N3O2.C22H23N3O2.C19H17N3O2/c33-26(18-20-15-16-21-9-7-8-14-24(21)17-20)32-29-27(28(34)23-12-5-2-6-13-23)31-25(19-30-29)22-10-3-1-4-11-22;31-24(18-10-13-20-11-4-1-5-12-20)30-27-25(26(32)22-16-8-3-9-17-22)29-23(19-28-27)21-14-6-2-7-15-21;30-23(17-16-19-10-4-1-5-11-19)29-26-24(25(31)21-14-8-3-9-15-21)28-22(18-27-26)20-12-6-2-7-13-20;29-22(16-18-10-4-1-5-11-18)28-25-23(24(30)20-14-8-3-9-15-20)27-21(17-26-25)19-12-6-2-7-13-19;1-3-15(2)22(27)25-21-19(20(26)17-12-8-5-9-13-17)24-18(14-23-21)16-10-6-4-7-11-16;1-13(23)21-19-17(18(24)15-10-6-3-7-11-15)22-16(12-20-19)14-8-4-2-5-9-14/h1-17,19,28,34H,18H2,(H,30,32,33);1-9,11-12,14-17,19,26,32H,10,13,18H2,(H,28,30,31);1-15,18,25,31H,16-17H2,(H,27,29,30);2-3,6-9,12-15,17-18,24,30H,1,4-5,10-11,16H2,(H,26,28,29);4-15,20,26H,3H2,1-2H3,(H,23,25,27);2-12,18,24H,1H3,(H,20,21,23).
What are the key properties of 2-cyclohexyl-N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]acetamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]acetamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-2-methylbutanamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-2-naphthalen-2-ylacetamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-4-phenylbutanamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-3-phenylpropanamide?
2-cyclohexyl-N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]acetamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]acetamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-2-methylbutanamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-2-naphthalen-2-ylacetamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-4-phenylbutanamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-3-phenylpropanamide has a molecular weight of 2360.85 g/mol, XLogP of 28.07, 37 rotatable bonds, 12 hydrogen bond donors, and 24 hydrogen bond acceptors.
Where does this data come from?
All data for 2-cyclohexyl-N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]acetamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]acetamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-2-methylbutanamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-2-naphthalen-2-ylacetamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-4-phenylbutanamide;N-[3-[hydroxy(phenyl)methyl]-5-phenylpyrazin-2-yl]-3-phenylpropanamide is sourced from PubChem (CID 157293632), the world's largest open chemistry database maintained by the National Library of Medicine (NIH).